Diagnostic stage discordance and survival in T2 bladder cancer: rethinking the clinical behavior of progressive disease
- 1Department of Urology, Uşak Training and Research Hospital, Uşak, Türkiye
- 2Department of Urology, Uşak University Faculty of Medicine, Ankara-İzmir Yolu 8. Km. 1 Eylül Kampüsü Yerleşkesi, Uşak, Türkiye
Abstract
Background: Progression from non–muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) remains a major clinical challenge, particularly at the T2 stage. This study aimed to evaluate pathological stage concordance and survival outcomes between patients with primary and progressive T2 MIBC following radical cystectomy (RC).
Methods: A total of 106 patients with clinical T2-stage bladder cancer who underwent RC were retrospectively analyzed. Patients were categorized as primary or progressive T2 based on their initial transurethral resection of bladder tumor (TUR-BT) pathology. Demographic, histopathological, and survival variables were compared between the two groups using appropriate statistical tests. Kaplan–Meier and univariable Cox regression analysis were performed to assess survival and prognostic factors.
Results: In the progressive group, T2 disease was identified on a subsequent TUR-BT, with a median interval of 3 (2–10) months. No significant difference was observed in stage concordance between TUR-BT and RC pathology between the primary and progressive T2 groups (p = 0.525). The mean number of positive lymph nodes was higher in the primary group (p = 0.012). Upper urinary tract recurrence was significantly more frequent in the progressive group (p = 0.007). No significant difference was observed in distant metastasis rates between the groups. Overall survival was also comparable (46.0 vs. 31.0 months, log-rank p = 0.329). Pathological stage at RC was the only factor significantly associated with overall survival.
Conclusion: Progressive T2 MIBC was not associated with significant differences in pathological stage concordance, distant metastasis rates, or overall survival compared with primary T2 disease. These findings suggest that progressive disease may not represent a more aggressive biological phenotype. Nevertheless, pathological stage discordance remained common in both groups, highlighting the limitations of clinical staging. Accurate stage assessment and timely radical cystectomy remain critical for the optimal management of T2 MIBC.
Related
- Diagnostic discordance between referral impressions, clinical assessment, and final electrodiagnostic findings.
- Molecular and Conventional Tests in Onychomycosis: A Systematic Review of Paired Diagnostic Discordance and Clinical Interpretation
- Diagnostic Discordance in a 46,XX Ovarian Dissecting Gonadoblastoma with Dysgerminoma Transformation and Leydig Cell Tumor: Hyperandrogenism, β-hCG Elevation, and CEUS Findings
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival
- Receptor Status Changes, HER2-Low Discordance, and TNBC Transformation in Metastatic Breast Cancer: Prognostic Significance and Impact on Survival Outcomes
BibTeX
@article{tuncekin2026diagnostic,
title = {{Diagnostic stage discordance and survival in T2 bladder cancer: rethinking the clinical behavior of progressive disease}},
author = {Adem Tunçekin and Yasin Aktaş and Hakan Türk and Arda Tongal},
journal = {BMC Urology},
year = {2026},
month = aug,
doi = {10.1186/s12894-026-02308-w},
url = {https://doi.org/10.1186/s12894-026-02308-w},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Diagnostic stage discordance and survival in T2 bladder cancer: rethinking the clinical behavior of progressive disease
AU - Adem Tunçekin
AU - Yasin Aktaş
AU - Hakan Türk
AU - Arda Tongal
PY - 2026
DA - 2026/08/08
JO - BMC Urology
DO - 10.1186/s12894-026-02308-w
UR - https://doi.org/10.1186/s12894-026-02308-w
AB - Background: Progression from non–muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) remains a major clinical challenge, particularly at the T2 stage. This study aimed to evaluate pathological stage concordance and survival outcomes between patients with primary and progressive T2 MIBC following radical cystectomy (RC). Methods: A total of 106 patients with clinical T2-stage bladder cancer who underwent RC were retrospectively analyzed. Patients were categorized as primary or progressive T2 based on their initial transurethral resection of bladder tumor (TUR-BT) pathology. Demographic, histopathological, and survival variables were compared between the two groups using appropriate statistical tests. Kaplan–Meier and univariable Cox regression analysis were performed to assess survival and prognostic factors. Results: In the progressive group, T2 disease was identified on a subsequent TUR-BT, with a median interval of 3 (2–10) months. No significant difference was observed in stage concordance between TUR-BT and RC pathology between the primary and progressive T2 groups (p = 0.525). The mean number of positive lymph nodes was higher in the primary group (p = 0.012). Upper urinary tract recurrence was significantly more frequent in the progressive group (p = 0.007). No significant difference was observed in distant metastasis rates between the groups. Overall survival was also comparable (46.0 vs. 31.0 months, log-rank p = 0.329). Pathological stage at RC was the only factor significantly associated with overall survival. Conclusion: Progressive T2 MIBC was not associated with significant differences in pathological stage concordance, distant metastasis rates, or overall survival compared with primary T2 disease. These findings suggest that progressive disease may not represent a more aggressive biological phenotype. Nevertheless, pathological stage discordance remained common in both groups, highlighting the limitations of clinical staging. Accurate stage assessment and timely radical cystectomy remain critical for the optimal management of T2 MIBC.
SN - 1471-2490
ER -